{
    "root": "b4ff12a6-841e-4eff-b9a4-bb814230eea5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "esomeprazole magnesium",
    "value": "20250228",
    "ingredients": [
        {
            "name": "ESOMEPRAZOLE MAGNESIUM",
            "code": "R6DXU4WAY9"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERYL MONO AND DIPALMITOSTEARATE",
            "code": "KC98RO82HJ"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE (110000 WAMW)",
            "code": "5Y0974F5PW"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        }
    ],
    "indications": "esomeprazole proton pump inhibitor ( ppi ) . esomeprazole magnesium delayed-release capsules indicated : short-term treatment healing erosive esophagitis ( ee ) adults pediatric patients 12 years 17 years age . ( 1.1 ) maintenance healing ee adults . ( 1.2 ) short-term treatment heartburn symptoms associated gerd adults pediatric patients 12 years 17 years age . ( 1.3 ) risk reduction nonsteroidal anti-inflammatory drugs ( nsaid ) -associated gastric ulcer adults risk developing gastric ulcers due age ( 60 years older ) and/or documented history gastric ulcers . ( 1.4 ) helicobacter pylori eradication adult patients reduce risk duodenal ulcer recurrence combination amoxicillin clarithromycin . ( 1.5 ) long-term treatment pathological hypersecretory conditions , including zollinger-ellison syndrome adults . ( 1.6 )",
    "contraindications": "population recommended adult ( 2.1 ) pediatric ( 2.2 ) healing ee ( 1 year older ) adults 20 mg 40 mg 1 daily 4 8 weeks ; patients may require additional 4 8 weeks 12 years 17 years 20 mg 40 mg 1 daily 4 8 weeks maintenance healing ee adults 20 mg daily . controlled extend beyond 6 months treatment symptomatic gerd adults 20 mg daily daily 4 weeks patients may require additional 4 weeks 12 years 17 years 20 mg daily 4 weeks risk reduction nsaid-associated gastric ulcer adults 20 mg 40 mg 1 daily 6 months 2 h. pylori eradication reduce risk duodenal ulcer recurrence adults esomeprazole 40 mg 1 daily 10 days amoxicillin 1000 mg twice daily 10 days 3 clarithromycin 500 mg twice daily 10 days 3 pathological hypersecretory conditions including zollinger-ellison syndrome adults starting 40 mg twice daily 4 ( varies individual patient ) long clinically indicated . 1 maximum 20 mg daily recommended patients severe liver impairment ( child-pugh class c ) . 2 controlled extend beyond 6 months . 3 refer amoxicillin clarithromycin prescribing information adjustments elderly renally-impaired patients . 4 starting 20 mg twice daily recommended patients severe liver impairment ( child-pugh class c ) . preparation information swallow capsules whole ; crush chew . patients swallow intact capsule , capsule opened , contents mixed applesauce . ( 2.3 ) opened capsules administered nasogastric tube . ( 2.3 )",
    "warningsAndPrecautions": "esomeprazole magnesium delayed-release capsules , usp 20 mg size ' 4 ' hard gelatin white opaque colored capsule , imprinted '186 ' cap '20 mg ' body filled white slightly yellow colored pellets . supplied follows : bottles 30 capsules child-resistant closure , ndc 70377-055-11 bottles 90 capsules child-resistant closure , ndc 70377-055-12 bottles 1,000 capsules , ndc 70377-055-13 esomeprazole magnesium delayed-release capsules , usp 40 mg size ' 3 ' hard gelatin white opaque colored capsule , imprinted '187 ' cap '40 mg ' body filled white slightly yellow colored pellets . supplied follows : bottles 30 capsules child-resistant closure , ndc 70377-056-11 bottles 90 capsules child-resistant closure , ndc 70377-056-12 bottles 1,000 capsules , ndc 70377-056-13 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) . [ usp controlled room temperature ] . keep esomeprazole magnesium delayed-release capsules container tightly closed . dispense tight container esomeprazole magnesium delayed-release capsules product package subdivided .",
    "adverseReactions": "esomeprazole magnesium delayed-release capsules contraindicated patients known hypersensitivity substituted benzimidazoles component formulation . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6.2 ) ] . information amoxicillin clarithromycin , indicated combination esomeprazole magnesium delayed-release capsules h. pylori eradication reduce risk duodenal ulcer recurrence , refer section respective prescribing information . proton pump inhibitors ( ppis ) , including esomeprazole magnesium delayed-release capsules , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] .",
    "indications_original": "Esomeprazole is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules are indicated for the: Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) Maintenance of healing of EE in adults. ( 1.2 ) Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 )",
    "contraindications_original": "Population Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Healing of EE (1 year and older) Adults 20 mg or 40 mg 1 once daily for 4 to 8 weeks; some patients may require an additional 4 to 8 weeks 12 years to 17 years 20 mg or 40 mg 1 once daily for 4 to 8 weeks Maintenance of Healing of EE Adults 20 mg once daily. Controlled studies do not extend beyond 6 months Treatment of Symptomatic GERD Adults 20 mg once daily once daily for 4 weeks some patients may require an additional 4 weeks 12 years to 17 years 20 mg once daily for 4 weeks Risk Reduction of NSAID-Associated Gastric Ulcer Adults 20 mg or 40 mg 1 once daily for up to 6 months 2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Adults Esomeprazole 40 mg 1 once daily for 10 days Amoxicillin 1000 mg twice daily for 10 days 3 Clarithromycin 500 mg twice daily for 10 days 3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Adults Starting dosage is 40 mg twice daily 4 (varies with the individual patient) as long as clinically indicated. 1 A maximum dosage of 20 mg once daily is recommended for patients with severe liver impairment (Child-Pugh Class C). 2 Controlled studies do not extend beyond 6 months. 3 Refer to the amoxicillin and clarithromycin prescribing information for dosage adjustments in elderly and renally-impaired patients. 4 A starting dosage of 20 mg twice daily is recommended for patients with severe liver impairment (Child-Pugh Class C). Preparation and Administration Information Swallow capsules whole; do not crush or chew. For patients who cannot swallow intact capsule, the capsule can be opened, and the contents mixed with applesauce. ( 2.3 ) Opened capsules can be administered through a nasogastric tube. ( 2.3 )",
    "warningsAndPrecautions_original": "Esomeprazole magnesium delayed-release capsules, USP 20 mg are size '4' hard gelatin white opaque colored capsule, imprinted with '186' on cap and '20 mg' on body and filled with white to slightly yellow colored pellets. They are supplied as follows:\n                  Bottles of 30 Capsules with child-resistant closure, NDC 70377-055-11\n                  Bottles of 90 Capsules with child-resistant closure, NDC 70377-055-12\n                  Bottles of 1,000 Capsules, NDC 70377-055-13\n                  Esomeprazole magnesium delayed-release capsules, USP 40 mg are size '3' hard gelatin white opaque colored capsule, imprinted with '187' on cap and '40 mg' on body and filled with white to slightly yellow colored pellets. They are supplied as follows:\n                  Bottles of 30 Capsules with child-resistant closure, NDC 70377-056-11\n                  Bottles of 90 Capsules with child-resistant closure, NDC 70377-056-12\n                  Bottles of 1,000 Capsules, NDC 70377-056-13\n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature]. Keep esomeprazole magnesium delayed-release capsules container tightly closed. Dispense in a tight container if the esomeprazole magnesium delayed-release capsules product package is subdivided.",
    "adverseReactions_original": "Esomeprazole magnesium delayed-release capsules are contraindicated in patients with known hypersensitivity to substituted benzimidazoles or to any component of the formulation. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria [see Warnings and Precautions (5.2), Adverse Reactions (6.2)].\n                     \n                     For information about contraindications of amoxicillin and clarithromycin, indicated in combination with esomeprazole magnesium delayed-release capsules for H. pylori eradication to reduce the risk of duodenal ulcer recurrence, refer to the Contraindications section of the respective prescribing information.\n                     Proton pump inhibitors (PPIs), including esomeprazole magnesium delayed-release capsules, are contraindicated in patients receiving rilpivirine-containing products [see Drug Interactions (7)]."
}